- Subject
- Nutrition
- Filed
- Source
- vcramer
- Loans
- 951
Survey Finds Diabetes Touches 63% of Americans, With Treatment Costs a Concern
A survey of 1,005 U.S. adults finds diabetes is widely present in people’s lives, while many see medication costs and uncertainty about AI as concerns.

Diabetes is part of life for many Americans: more than 63% of adults surveyed said at least one close family member, friend, or coworker has been diagnosed with diabetes or prediabetes. The findings also point to concerns about treatment affordability and mixed views on using artificial intelligence to guide diabetes care. They describe public perceptions, not patients’ clinical experiences or the effectiveness of particular treatments.

The American Diabetes Association commissioned Ipsos to survey 1,005 U.S. adults online in English on October 29 and 30, 2026. The nationally representative sample included adults aged 18 and older. The stated credibility interval is plus or minus 3.8 percentage points for all respondents, so the reported percentages are estimates and should be read with that uncertainty in mind. The survey does not establish why respondents hold these views or whether they reflect the experiences of people living with diabetes.
Medication costs stand out as a perceived barrier
More than half of respondents, 56%, said the cost of GLP-1-based medications used to treat obesity and diabetes can prevent people who might benefit from accessing them. About one in four respondents, 26%, described that barrier as very significant. These results capture a broad public view; they do not measure how many people have been unable to obtain a prescription or continue treatment because of cost.
Insulin costs were also a concern in a separate ADA survey conducted earlier in 2026. In that survey, 72% of respondents said they paid more than $35 per month for insulin, and nearly 40% reported paying more than $150 monthly. The two surveys address different questions, and their results shouldn’t be treated as a direct comparison of medication prices or access across all U.S. patients. Individual costs can depend on coverage, the medication prescribed, and other circumstances.
For people weighing treatment options, these findings reinforce that affordability can be part of a care discussion. A clinician or pharmacist can help explain expected costs, coverage questions, and available treatment choices for an individual’s situation. The survey itself does not recommend a medication or establish that any one treatment is appropriate for a particular person.
Views on research progress and AI are mixed
Half of respondents said a major advance in treating type 1 diabetes is likely within the next 10 years. That figure reflects optimism, rather than evidence that a specific advance is imminent. The survey does not define what respondents considered a major advance, and it cannot predict the timing or outcome of research. Progress in diabetes care can take time to move from early investigation to treatments that are shown to help people in clinical studies.
Respondents were less settled about artificial intelligence in diabetes management. Thirty-two percent said they would feel comfortable with AI tools making real-time recommendations, while 37% said they would feel uncomfortable. Discomfort was reported by 44% of Boomers and 30% of Millennials, the largest generational difference described in the results. The remaining responses aren’t detailed in the findings provided.
These answers measure comfort, not whether AI tools are accurate, safe, or useful in practice. A real-time recommendation could affect decisions about daily care, so the tool’s design, evidence, and role in a person’s care matter. The survey offers no assessment of any particular product. People considering digital tools can ask their care team how recommendations are checked and how they fit alongside advice from clinicians.
What the findings can—and can’t—tell readers
The survey offers a snapshot of how U.S. adults view diabetes, costs, research, and technology. Its broad sample can help identify topics that matter to the public, but it doesn’t show that the respondents with a close connection to diabetes share the same views as people diagnosed with the condition. Nor does it measure the quality of care, medication use, or health outcomes.
That distinction is especially important when interpreting views on cost and future treatment advances. Likewise, confidence that research will lead to progress is not proof that a particular therapy will be available within a set timeframe.
For families affected by diabetes, the practical takeaway is to bring specific questions about treatment costs, care choices, and technology to a clinician or pharmacist. The survey points to issues people are thinking about; personal medical decisions still depend on a person’s health, care plan, and circumstances.